anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PROBLEM TO BE SOLVED: To obtain a solid powder cosmetic having excellent antiseptic effect without requiring mixing of an antiseptic agent and having high safety with low irritation by containing powder treated with a polyhydric alcohol. SOLUTION: This solid powder cosmetic contains 0.05-5wt.% based on total amount of the cosmetic of cosmetic powder obtained by treating powder with a polyhydric alcohol as an active component. The powder is treated by a mixing and stirring device such as a Henschel mixer and the powder (e.g. silicic acid anhydride) as it is, or is dispersed in a solvent (e.g. ethanol) and the resultant dispersion is dissolved in a polyhydric alcohol (e.g. 1,3-butylene glycol) while blending, then the solution is sprayed or dropped, thus dried. The resultant powder can be prepared to a solid powder cosmetic such as powder foundation, cheek rouge, eye shadow or body powder.
The most common manifestation of endometriosis, a condition characterized by the presence of endometrial-like tissue outside of the uterus, is the endometrioma, a cystic ovarian lesion. It is a commonly occurring condition associated with chronic pelvic pain exacerbated prior to and during menstruation, as well as infertility. The exact pathomechanisms of the endometrioma are still not fully understood. Emerging evidence suggests a pivotal role of immune dysregulation in the pathogenesis of endometriomas, primarily influencing both local and systemic inflammatory processes. Among the factors implicated in the creation of the inflammatory milieu associated with endometriomas, alterations in both serum and local levels of several cytokines stand out, including IL-6, IL-8, and IL-1β, along with abnormalities in the innate immune system. While numerous signaling pathways have been suggested to play a role in the inflammatory process linked to endometriomas, only NF-κB has been conclusively demonstrated to be involved. Additionally, increased oxidative stress, both resulting from and contributing to endometriomas, has been identified as a primary driver of both systemic and local inflammation associated with the condition. This article reviews the current understanding of immune dysfunctions in the endometrioma and their implications for inflammation.
PURPOSE:To obtain an inexpensive master batch having a high perfume content and low evaporation loss of perfume during molding, by adding the perfume and a polyolefin in turn to an ethylene/vinyl acetate copolymer powder with high speed agitation and kneading the mixture. CONSTITUTION:50pts.wt. or above perfume is added to 100pts.wt. ethylene/vinyl acetate copolymer (EVA), and the mixture is kneaded at a high speed. Polyolefin powder is added thereto and agitated at a high speed to obtain a granular master batch. The EVA powder used is usually one containing 5-45wt% vinyl acetate and includes also its modified resin. Examples of the perfumes used include lemon oil, lavender oil, alpha-pinene and camphene and compounded perfumes thereof. When the amount of the perfume used is below 50pts.wt., the mixture does not form a gel and even when the polyolefin powder is added afterwards, formation of granules is difficult.
PURPOSE: Medial open-wedge high tibial osteotomy (OWHTO) is related to cartilage improvement in the medial compartment. This study aimed to evaluate factors associated with cartilage improvement and patient-reported outcomes (PRO) after OWHTO. It was hypothesised that cartilage improvement is associated with favourable PRO.
METHODS: This retrospective study included 94 patients who underwent OWHTO. The mean follow-up period was 5 years. The weight-bearing line ratio (WBLR) was defined as the ratio of the distance from the medial tibial edge to the tibial insertion of the weight-bearing line and the tibial width. The International Cartilage Research Society grade evaluated the medial femoral condyle (MFC) and medial tibial plateau (MTP) at initial and second-look arthroscopy, and cartilage improvement after OWHTO was assessed. Postoperative knee injury and osteoarthritis outcome scores (KOOS) were compared between the groups with improved and non-improved cartilage. Additionally, factors related to cartilage improvement and postoperative KOOS scores were analysed.
RESULTS: Regarding the MFC, KOOS pain, symptoms, activities of daily living (ADL) and quality of life (QOL) were significantly higher in the cartilage-improved group than in the non-improved group (p = 0.012, 0.003, 0.001, 0.006), and cartilage improvement was significantly related to KOOS pain, ADL and QOL (p = 0.021, 0.039, 0.013). In addition, the postoperative WBLR was associated with cartilage improvement, with a cutoff value of 54.0% (p = 0.046). Regarding the MTP, KOOS ADL and QOL (p = 0.026, 0.022) were significantly higher in the cartilage-improved group than in the nonimproved group. Body mass index (BMI) was significantly related to the postoperative QOL (p = 0.018) and associated with cartilage improvement, with a cutoff value of 25.9 kg/m2 (p = 0.002).
CONCLUSION: A postoperative WBLR greater than 54.0% and a preoperative BMI below 25.9 kg/m2 were associated with cartilage improvement, positively impacting PRO after OWHTO.
LEVEL OF EVIDENCE: Level III, retrospective comparative study.
Neutrophils exacerbate pulmonary ischemia-reperfusion injury (IRI) resulting in poor short and long-term outcomes for lung transplant recipients. Glycolysis powers neutrophil activation, but it remains unclear if neutrophil-specific targeting of this pathway will inhibit IRI. Lipid nanoparticles containing the glycolysis flux inhibitor 2-deoxyglucose (2-DG) were conjugated to neutrophil-specific Ly6G antibodies (NP-Ly6G[2-DG]). Intravenously administered NP-Ly6G(2-DG) to mice exhibited high specificity for circulating neutrophils. NP-Ly6G(2-DG)-treated neutrophils were unable to adapt to hypoglycemic conditions of the lung airspace environment as evident by the loss of demand-induced glycolysis, reductions in glycogen and ATP content, and an increased vulnerability to apoptosis. NP-Ly6G(2-DG) treatment inhibited pulmonary IRI following hilar occlusion and orthotopic lung transplantation. IRI protection was associated with less airspace neutrophil extracellular trap generation, reduced intragraft neutrophilia, and enhanced alveolar macrophage efferocytotic clearance of neutrophils. Collectively, our data show that pharmacologically targeting glycolysis in neutrophils inhibits their activation and survival leading to reduced pulmonary IRI.
The invention discloses a quality control method for Kouyanqing granules, which comprises the following steps: preparing and mixing a reference substance solution; preparing a methanol solution of theThe invention discloses a quality control method for Kouyanqing granules, which comprises the following steps: preparing and mixing a reference substance solution; preparing a methanol solution of theKouyanqing granules as a test solution; analyzing the reference substance solution and the test solution by a high performance liquid chromatography to obtain a high efficiency liquid chromatography   Kouyanqing granules as a test solution; analyzing the reference substance solution and the test solution by a high performance liquid chromatography to obtain a high efficiency liquid chromatography finger print of the Kouyanqing granules; and comparing and monitoring the quality of the Kouyanqing granules according to a chromatogram map of the reference substance solution and a finger print of tfinger print of the Kouyanqing granules; and comparing and monitoring the quality of the Kouyanqing granules according to a chromatogram map of the reference substance solution and a finger print of the test solution. The invention also discloses application of the quality control method in identifying the Kouyanqing granules. The quality control method adopts the high efficiency liquid chromatogrhe test solution. The invention also discloses application of the quality control method in identifying the Kouyanqing granules. The quality control method adopts the high efficiency liquid chromatography to establish the finger print of the Kouyanqing granules, and can monitor the stability of technical processes for producing semi-finished products and finished products through the established saphy to establish the finger print of the Kouyanqing granules, and can monitor the stability of technical processes for producing semi-finished products and finished products through the established standard finger print. The method effectively avoids counterfeiting of products, ensures normal production and circulation order of the products, and has outstanding practicability.                    tandard finger print. The method effectively avoids counterfeiting of products, ensures normal production and circulation order of the products, and has outstanding practicability.
The invention relates to a predictive system for generating a clinical query. Methods, systems, and apparatus, including computer programs encoded on computer storage media, for generating a prediction system that obtains and processes data describing terms of different medical concepts to generate commands from user queries. An entity module of the system determines whether the term describes a medical entity associated with a healthcare condition affecting the individual. In the case where the term describes a medical entity, the encoding module links the medical entity with a specified category based on the encoding scheme. The system receives a user query. A parsing engine of the system uses the received query to generate machine-readable commands by parsing the query against terms describing the medical entity and based on an encoding scheme used to link the medical entity to the specified categories. The system uses the command to query in a different database to obtain data for generating a response to the received query.
Throughout the study, each week participants will be asked to plan two exercise sessions for the upcoming week, and will be asked to report on how they did with those plans at the end of the day when they planned to exercise. At the very beginning of the time window when they planned to exercise participants will be randomized with 40% probability to receive no message, 20% probability to receive a reminder to fill out the study questionnaire at the end of the day, and 40% probability to receive one of two types of affective rewards messages (active intervention). The two types are: 1) low-reflection messages written by participants at the beginning of the study, about the affective rewards of exercise they have previously experienced; and 2) high-reflection messages that prompt participants to reflect on the affective rewards of exercise and text back a response.
In Stage 1, starting dose of atezolizumab will be 1200 mg IV q3w administered on Day 8 of Cycle 1 and on Day 1 (21-day cycle) of each cycle thereafter along with alectinib at a starting dose of 600 mg PO BID for 28 consecutive days during Cycle 1 and on Days 1-21 of each cycle thereafter; unless maximum tolerable dose (MTD) is exceeded. The combination will be given to treatment-naive participants with ALK-positive, locally advanced or metastatic NSCLC.
Trametinib will be dosed at 1mg, 1.5mg, and 2mg orally (PO) daily based on Phase I data of this drug as a single agent. All patients entering this study will receive intravenous (IV) nab-paclitaxel on Day 1, 8, and 15. Dose levels will be assigned to each patient, and dose escalation decisions will be based on the evaluation of safety data from the prior cohort.
Cognitive Processing Therapy - Cognitive (CPT-C), is a brief cognitive behavioral treatment for PTSD. CPT-C consists of 2 hours of therapy each week for 6 weeks (i.e., two sessions).
Patients without symptom improvement or with partial response under intensive behavioural protocol and medical therapy (at least 2 different antimuscarinic agents) will be recruited. Patients with significantly bothersome S/E on antimuscarinics will also be included.
1. Technical Result Widening of assortment of laxative medicament forms made from plant raw. 2. Essence There is provided a laxative preparation easily soluble in the stomach in the form of capsule, which comprises fruits of common buckthorn Rhamnus catharica L., or anise Pimpinella anisum L., or rhubarb Rheum or leaves of cassia Cassia Acutifolia Del., or dried plum Prunus domestica, or dried fig Ficus carica L., or laminaria Laminaria japonica Aresch, or buckthorn bark, Rhamnus frangula L. or fruits thereof. 3. Field of Application Medicine, therapy
In Week 1, 2, and 3 subjects will attend the HEART CAMP. Subjects will set specific exercise goals. Subjects will be taught how to record exercise data on the computer at the exercise facility. Specific activities will teach subjects aerobic and resistance training exercises and build self-efficacy to exercise. During the period from month 3 to the end of study subjects will continue the training program independently and no formal sessions will be scheduled.
Adult T1DM patients, aged 18-75 years, regularly attending the out-patient diabetes clinic of the Antwerp University Hospital are recruited starting from June 2011. Patients had to have a diabetes duration of ≥5 years and be in general good health to be included. Exclusion criteria were a history of a major adverse cardiovascular event (myocardial infarction, stroke), other cardiovascular complaints, pregnancy or a glomerular filtration rate ≤30 ml/min/1.73 m2.
Sodium ferric gluconate complex in sucrose injection, an iron replacement product, is a stable macromolecular complex with an apparent molecular weight on gel chromatography of 289,000 – 440,000 daltons. The macromolecular complex is negatively charged at alkaline pH and is present in solution with sodium cations. The product has a deep red color indicative of ferric oxide linkages. The chemical name is D-Gluconic acid, iron (3+) sodium salt. 

The structural formula is considered to be [NaFe2O3(C6H11O7)(C12H22O11)5]n≈200. 

Each sterile, single dose vial of 5 mL of sodium ferric gluconate complex in sucrose injection for intravenous injection contains 62.5 mg (12.5 mg/mL) of elemental iron as the sodium salt of a ferric ion carbohydrate complex in an alkaline aqueous solution with approximately 20% sucrose w/v (195 mg/mL) in water for injection, pH 7.7 - 9.7. 

Each mL contains 9 mg of benzyl alcohol as an inactive ingredient.
The chronic diseases, including diabetes mellitus (DM) are a major public health problems of today. There is evidence that glycated hemoglobin (A1C) levels above 7% are associated with a progressively greater risk of chronic complications related to DM. However, approximately 60% of diabetics do not achieve glycemic control. In Brazil, pharmacists are not involved in direct care of patients with DM. The investigators conducted a randomized controlled trial, for six months, in Ouro Preto, Minas terais to determine the effect of pharmaceutical intervention on glycemic control in patients with diabetes and hyperglycemic (A1C \> 7%). One hundred and twenty-nine subjects were randomized to receive usual care only or usual care and pharmaceutical intervention. The population of those who had access in the brazilian public health care system, as consultations with doctors, nurses and nutritionists, laboratory tests and access to essential medicines were considered as conventional health care.
Dermatopathy   
Skin lesions ranging from erythema to necrosis were seen in repeated-dose toxicology studies in both rats and monkeys. The etiology of these skin lesions is unknown. At the maximum recommended human dose (MRD) of 600 mg/day, there is a 2-fold safety margin for the dermatological lesions. The more severe dermatopathies involving necrosis were associated with pregabalin exposures (as expressed by plasma AUCs) of approximately 3 to 8 times those achieved in humans given the MRD. No increase in incidence of skin lesions was observed in clinical studies. 

Ocular Lesions   
Ocular lesions (characterized by retinal atrophy [including loss of photoreceptor cells] and/or corneal inflammation/mineralization) were observed in two lifetime carcinogenicity studies in Wistar rats. These findings were observed at plasma pregabalin exposures (AUC) greater than or equal to 2 times those achieved in humans given the maximum recommended dose of 600 mg/day. A no-effect dose for ocular lesions was not established. Similar lesions were not observed in lifetime carcinogenicity studies in two strains of mice or in monkeys treated for 1 year.
Larotinib , capsules (150mg\*2+50mg\*1), at Hour 0 on Day 1 followed by an overnight fast. On Days 15 to Day 25, participants received itraconazole 200 mg solution, orally, once daily (QD) on Days 15 to Day 25 and a single oral dose of Larotinib 350 mg as capsule was coadministered on Day 19 (Treatment B). There was a washout period of 13 days between the two treatments.
The present invention discloses a traditional Chinese medicine for treating coronary disease and angina pectoris, which is mainly formed by preparing red ginseng, chuanxiong rhizome, corydalis tuber, grassleaved sweetflag rhizome, aurantii immaturus, earthworm, Chinese honeylocust spine, cassia twig and borneol based on certain weight portions. The traditional Chinese medicine can be prepared into various kinds of common oral administration preparation such as capsules, granules, etc. The medicine has the functions for benefiting qi, activating blood, invigorating collateral and alleviating pain. The traditional Chinese medicine is relatively effective traditional Chinese medicine preparation for treating coronary disease and angina pectoris. The verification of animal experiments and clinical experiments shows that the preparation of the present invention has the advantages of good therapeutic effect, rapid and lasting action, no toxic or side effect and the like. The present invention provides a preparation technology.
BACKGROUND: Sarcopenic obesity (SO) in nursing home residents is rarely studied. We aimed to evaluate and compare the prevalence and consistency of different SO diagnostic methods and to investigate which criterion demonstrated a stronger association with instrumental activities of daily living (IADL) disability.
METHODS: We consecutively recruited older adults aged ≥ 60 years, residing in 15 nursing homes in Zigong City, China. Sarcopenia obesity was defined according to the European Society for Clinical Nutrition and Metabolism (ESPEN) and the European Association for the Study of Obesity criteria (SOESPEN), recommending skeletal muscle mass (SMM) adjusted by body weight (SMM/W) to identify low muscle mass. Further, we adapted ESPEN criteria (SOESPEN-M) by employing SMM adjusted by body mass index (SMM/BMI).
RESULTS: We included 832 participants (median age 73.0 years, 296 women). The prevalence of SOESPEN and SOESPEN-M was 43.5% and 45.3%, respectively. SOESPEN showed good consistency with SOESPEN-M (Cohen's kappa = 0.759). More than one-third of participants in the normal weight group were diagnosed with SOESPEN or SOESPEN-M. Even within the underweight group, the prevalence of SOESPEN and SOESPEN-M was 8.9% and 22.2%, respectively. Participants with IADL disability had significantly lower SMM/W and SMM/BMI, but higher fat mass percentage of body weight (FM%) than participants without IADL disability. After full adjustment for potential confounders, SOESPEN-M (OR 1.68, 95% CI 1.21 to 2.32), but not SOESPEN (OR 1.28, 95% CI 0.93 to 1.75), remained significantly associated with IADL disability.
CONCLUSIONS: Both SOESPEN and SOESPEN-M showed a high prevalence among nursing home residents, even among individuals with underweight or normal weight. While SOESPEN had a good consistency with SOESPEN-M, only SOESPEN-M was independently associated with IADL disability. Screening and diagnosis of SO should be conducted in nursing home residents irrespective of BMI.
The present invention relates to generation and high level expression of recombinant non-toxic of epsilon toxin of  Clostridium perfringens  as a recombinant vaccine against  Clostridium perfringens  infection and a process for producing the vaccine involving amplifying, cloning, transforming, incubating and purifying the recombinant non-toxic epsilon toxin protein. Thus in this invention, substitution mutation Y71G was executed in recombinant Etx and the recombinant EtxY71G protein was over-expressed in soluble form. Expressed protein was purified near homogeneity by DEAE sepharose anion exchange chromatography with high yield. Potential of rEtxY71G as a vaccine candidate was evaluated and found to be highly specific and immunogenic. The present invention is the first report for high level expression of non toxic rEtxY71G mutant protein of  Clostridium perfringens.  Upto 100 mg/L of highly immunogenic and homogeneous recombinant EtxY71G protein of 31 kDa was produced. Further, the immunization with rEtxY71G gave very high titer and conferred protection against epsilon toxin intoxication.
The present disclosure provides activatable and detectable membrane-interacting peptides that, following activation, can interact with phospholipid bilayers, such as cell membranes. The present disclosure also provides methods of use of such compounds. The compounds of the present disclosure are of the general structure X 1a -A-X 2 —Z—X 1b , where A is a membrane-interacting peptide region having a plurality of nonpolar hydrophobic amino acid residues that, following separation from portions Z, is capable of interaction with a phospholipid bilayer; Z is an inhibitory peptide region that can inhibit the activity of portion A; X 2  is a cleavable linker that can be cleaved to release cleavage products from the compound; and X 1a  and X 1b  are optionally-present chemical handles that facilitate conjugation of various cargo moieties to the compound. Prior to cleavage of the composition at X 2 , the composition acts as a promolecule that does not associate with cellular membranes to a significant or detectable level. Following cleavage at cleavable linker X 2 , the cleavage product including portion A is free to interact with a phospholipid bilayer (e.g., a cell membrane), and thus accumulate at a site associated with a cleavage-promoting environment. Detection of the membrane-associated cleavage product can be accomplished by detection of a moiety attached through X 1a  and/or X 1b . Such compositions can be used in a variety of methods, including, for example, use in directly imaging active clotting within a subject.
AIM: To elucidate the effects of ultra-processed foods (UPFs) on body weight and ad libitum energy intake compared with non-UPFs.
MATERIALS AND METHODS: In this randomized, open-label crossover study conducted at the University of Tokyo Hospital, overweight/obese Japanese male participants were randomly assigned (1:1) to start the study with consumption of either UPFs or non-UPFs for 1 week, followed by a 2-week washout period, before crossing over to the alternate food diet for 1 week. Individuals with diabetes, hypertension or any other medical conditions who visited a hospital regularly were excluded. The meals were designed to be matched for the total energy and macronutrient levels. The primary outcome was the difference in the body weight change between the UPF and non-UPF periods. The differences in the average daily energy intake and chewing frequency were assessed as one of the prespecified secondary outcomes.
RESULTS: Nine eligible participants were randomly assigned to start the study with either UPFs or non-UPFs. All participants completed the study. During the UPF period, participants gained 1.1 kg more weight (95% confidence interval 0.2 to 2.0; P = .021) and consumed 813.5 kcal more per day (342.4 to 1284.7; P = .0041) compared with during the non-UPF period. Regarding the chewing frequency, the number of chews per calorie was significantly lower during the UPF period (P = .016).
CONCLUSIONS: Consumption of UPFs causes significant weight gain. Medical nutritional therapy focused on reducing the consumption of UPFs could be an effective strategy for preventing obesity.